# Alistair Watson

> Alistair Watson is a Series B investor at Aberdeen Standard Investments backing FinTech. See 6 investments, check sizes, portfolio and contact details…

- Type: Angel Investor
- Fund: [Aberdeen Standard Investments](https://shizune.co/investors/profile/aberdeen-standard-investments)
- Location: Edinburgh, United States
- Total investments: 6
- Last investment: Jan 2025
- Lead investor: 83%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/alistair-watson-3a806935/

Alistair Watson is a head of Strategy Innovation. Attended University of Oxford.

## Contacts

5 contacts available for Alistair Watson: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/alistair-watson-6f79?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| FinTech | 1 | 17% |
| Genetics | 1 | 17% |
| Software | 1 | 17% |
| Mobile Apps | 1 | 17% |
| Open Source | 1 | 17% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 33% |
| Series A | 1 | 17% |
| Funding Round | 1 | 17% |
| Debt Financing | 1 | 17% |
| Private Equity | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 2 | 33% |
| France | 1 | 17% |
| The Netherlands | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Latour Capital | In creating the VCF Latour Capital at the request of some great French entrepreneurs, we wanted to build a new tool entirely focused investment , majority LBO in business to potential. |  | Private Equity | Jan 22, 2025 |  |
| Eagle Genomics | Eagle Genomics is a enterprise software solutions company whose products enable the management, orchestration and exploitation of genomics and other life sciences data. They help Life Science companies get the maximum value from their R&D data and they are delivering the information architecture for the genomics era. Their suite of softwareproducts radically reduces cost and time to complete research, enabling drastic productivity improvements.Their architecture translates data sets into data assets, redefining the current paradigm in the industry, enabling the objective measurement of the value of digital assets and providing clarity on “return on information”. Their mix of expertise in biology, bioinformatics, data science and enterprise-class software engineering is unique in the field and has been applied over the last decade to solve their customers’ challenges in areas as diverse as drug development, personal hygiene and plant breeding.With global customers in the pharmaceuticals, fast moving consumer goods and agri-tech industries they understand the common challenges facing these industries in the handling of ever growing of data and information resources. Eagle Genomics is at the forefront in addressing the challenges, risks, and opportunities in delivering the enterprise information architecture for the genomics era. |  |  | Oct 31, 2022 |  |
| Eagle Genomics | Eagle Genomics is a enterprise software solutions company whose products enable the management, orchestration and exploitation of genomics and other life sciences data. They help Life Science companies get the maximum value from their R&D data and they are delivering the information architecture for the genomics era. Their suite of softwareproducts radically reduces cost and time to complete research, enabling drastic productivity improvements.Their architecture translates data sets into data assets, redefining the current paradigm in the industry, enabling the objective measurement of the value of digital assets and providing clarity on “return on information”. Their mix of expertise in biology, bioinformatics, data science and enterprise-class software engineering is unique in the field and has been applied over the last decade to solve their customers’ challenges in areas as diverse as drug development, personal hygiene and plant breeding.With global customers in the pharmaceuticals, fast moving consumer goods and agri-tech industries they understand the common challenges facing these industries in the handling of ever growing of data and information resources. Eagle Genomics is at the forefront in addressing the challenges, risks, and opportunities in delivering the enterprise information architecture for the genomics era. | $19.8M | Series B | Oct 31, 2022 |  |
| Titanbay | Titanbay is Europe’s fastest growing private markets infrastructure provider, dedicated to making private markets simpler and more accessible. Our integrated platform connects asset managers and distributors, providing the essential technology, operations, and regulatory framework required to effectively manage private market funds. We supportevery stage of the investment lifecycle, including fund structuring, onboarding, capital flows, reporting, compliance, and third-party integrations. Whether you’re raising capital, distributing funds, or expanding your private markets offering, Titanbay reduces complexity and enhances operational efficiency, so you can prioritise your clients and growth. |  | Series A | May 25, 2022 |  |
| Dott | Dott offers dock-less, shared electrical scooters, and bikes as alternatives for short-distance travel.The company is a micro-mobility European start-up, gathering the most experienced team in mobility and tech in Europe. We recently raised an initial investment of €20 million, co-led by EQT Ventures and Naspers. Dott is headquartered inAmsterdam and is gathering the most experienced team in mobility and tech in Europe. |  | Debt Financing | Jan 31, 2022 |  |
| Dott | Dott offers dock-less, shared electrical scooters, and bikes as alternatives for short-distance travel.The company is a micro-mobility European start-up, gathering the most experienced team in mobility and tech in Europe. We recently raised an initial investment of €20 million, co-led by EQT Ventures and Naspers. Dott is headquartered inAmsterdam and is gathering the most experienced team in mobility and tech in Europe. | $70M | Series B | Jan 31, 2022 |  |

6 of 6 investments shown.

## Co-investors
- [AXA Investment Managers](https://shizune.co/investors/profile/axa-investment-managers) — VC Fund, 2 deals together
- [EQT Ventures](https://shizune.co/investors/profile/eqtventures) — VC Fund, 2 deals together
- [ETF Partners](https://shizune.co/investors/profile/etf-partners) — VC Fund, 2 deals together
- [Granpool Innovative Investments](https://shizune.co/investors/profile/granpool) — VC Fund, 2 deals together
- [Prosus Ventures](https://shizune.co/investors/profile/prosus-ventures) — VC Fund, 2 deals together
- [Sofina](https://shizune.co/investors/profile/sofina) — VC Fund, 2 deals together

## About Aberdeen Standard Investments

VC Fund · Aberdeen, United Kingdom

Standard Life Aberdeen plc is one of the world’s largest investment companies, created in 2017 from the merger of Standard Life plc and Aberdeen Asset Management PLC. Operating under the brand Aberdeen Standard Investments, the investment arm manages £569.7bn* of assets, making it the largest active manager in the UK and the second-largest inEurope. It has a significant global presence and the scale and expertise to help clients meet their investment goals.

5 contacts available at Aberdeen Standard Investments.

| Name | Title | Profile |
| --- | --- | --- |
| Alan Gauld | Investment Director | https://shizune.co/investors/profile/alan-gauld |
| Alistair Watson | Head of Strategy Innovation | — |
| Dave Winter | Chief Operating Officer - Americas | — |
| John Sievwright | Trustee | — |
| Mary Drabble | Principal Data Governance Analyst | — |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Alistair Watson invest in?

Alistair Watson invests primarily in FinTech, Genetics and Software startups, most often at Series B and Series A stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Alistair Watson?

Public channels for Alistair Watson include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Alistair Watson last invest?

The most recent investment recorded for Alistair Watson closed in Jan 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co